恒瑞医药(600276.SH)：HRS-4729注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-4729 injection, a self-developed peptide drug aimed at improving metabolic regulation and weight loss [1] Group 1: Product Development - HRS-4729 injection is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR, which enhances metabolic regulation compared to dual-target therapies [1] - The drug promotes energy expenditure, fatty acid oxidation, and lipid breakdown, leading to better weight loss and reduction of liver fat [1]